The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| FGEN | +41.05% | -98.93% | -59.62% | -98% |
| S&P | +12.65% | +91.73% | +13.89% | +230% |
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
Its pipeline is looking thin, and it might hit another speed bump quite soon.
A noted investment bank takes a dimmer view of the company's stock.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.35M | -97.3% |
| Gross Profit | $1.04M | -97.7% |
| Gross Margin | 77.30% | -12.5% |
| Market Cap | $21.42M | -75.9% |
| Market Cap / Employee | $0.10M | 0.0% |
| Employees | 225 | -53.7% |
| Net Income | -$13.68M | 12.0% |
| EBITDA | -$11.44M | -12.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $23.37M | -83.4% |
| Accounts Receivable | $0.14M | -97.9% |
| Inventory | 3.9 | -84.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $19.40M | -86.9% |
| Short Term Debt | $73.73M | 374.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -23.85% | 17.8% |
| Return On Invested Capital | 48.96% | 37.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $12.67M | 131.8% |
| Operating Free Cash Flow | $12.68M | 131.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.17 | -0.24 | -0.14 | -0.10 | -74.61% |
| Price to Sales | 0.22 | 0.34 | 0.30 | 0.40 | -21.95% |
| Price to Tangible Book Value | -4.13 | -5.47 | -3.47 | -0.10 | -98.98% |
| Enterprise Value to EBITDA | 17.53 | -22.97 | -9.05 | -11.64 | -23.42% |
| Total Debt | $92.98M | $90.21M | $91.22M | $93.13M | -43.14% |
No podcast episodes available.
FGEN earnings call for the period ending September 30, 2021.
FGEN earnings call for the period ending June 30, 2021.
FGEN earnings call for the period ending March 31, 2021.
FGEN earnings call for the period ending January 31, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
